The first dose of the nation’s third coronavirus vaccine was administered Tuesday to an 86-year-old woman at Ohio State University.
“I wanted this shot,” Barbara Schmalenberger told a reporter. “I didn’t want to settle for anything else.”
Nearly 4 million doses of Johnson & Johnson’s newest COVID-19 vaccine were shipped Sunday night and were being delivered Tuesday to states for injections.
THE FIRST Johnson & Johnson vaccine has been administered in the United States. 86-year-old Barbara Schmalenberger was the first here at Ohio State University. “I wanted this shot,” she just told me. “I didn’t want to settle for anything else.” pic.twitter.com/kCNE9QyrkS
The White House said the entire stockpile of the newly approved single-dose Johnson & Johnson vaccine will go out immediately. J&J will deliver about 16 million more doses by the end of March and 100 million total by the end of June, but the distribution would be backloaded.
Also Tuesday, the White House announced that Merck & Co. will help produce J&J’s newly approved coronavirus vaccine in an effort to expand supply more quickly.
The announcement came as the White House looks to speed the production of the single-dose vaccine. Officials have said J&J faced unexpected production issues with its vaccine and produced only 3.9 million doses ahead of its receiving emergency use authorization Saturday. The company says it is on pace to deliver 100 million doses by the end of June.
White House press secretary Jen Psaki said the federal government was increasing supply of vaccines to states next week to 15.2 million doses per week, up from 14.5 million previously. States will also receive 2.8 million doses of the J&J shot this week.
Facing questions about the company’s slipping delivery schedule, J&J Vice President Richard Nettles told lawmakers on Capitol Hill last week that the company had faced “significant challenges” because of its “highly complex” manufacturing process.
The assistance from Merck was expected to help J&J meet its production commitments and expand supply even further, but the administration did not immediately provide specifics.
Psaki said an “across the administration effort” was required to get the two historic rivals to work together on the vaccines, even though conversations between the two companies have been going on for months.
“There’s a difference between conversations and it moving forward,” she said.
President Joe Biden is set to highlight the development in a speech Tuesday afternoon, as his administration now expects to have enough supply of the three approved vaccines to inoculate all eligible American adults by June — though actually delivering the injections could take longer.
It was not immediately clear when the effect of Merck’s assistance would be reflected in supply. Previously, federal officials have cautioned that setting up the highly specialized manufacturing lines to produce vaccines would take months.
The White House said Merck would devote two plants to the production process. One would make the vaccine and the other would handle inserting the vaccine into vials and ensuring strict quality controls. Psaki said the Biden administration was using its powers under the Defense Production Act to help Merck retool to work on the production.
Merck halted its own plans to develop a coronavirus vaccine earlier this year, finding that its candidates were generating an inferior immune system response compared with other vaccines. It said it would instead focus its work on developing treatments for COVID-19.
Compared with the two-dose versions produced by Moderna and Pfizer, the J&J vaccine is less resource intensive to distribute and administer, making it a critical piece to U.S. plans to spread vaccinations around the world — but only once Americans are inoculated. The J&J vaccine can be stored for months at refrigerated temperatures, rather than frozen, and doesn’t require patients to return for a second dose three or four weeks later.